Literature DB >> 2449832

Lavage angiotensin-converting enzyme as a marker of lung injury.

J Kelley1.   

Abstract

The source of angiotensin-converting enzyme (ACE) in lavage fluid remains controversial. I reassessed the levels of ACE in lavage fluid in contrasting models of lung injury in rats. In all 3 models examined, there was at least a 3-fold elevation in both ACE activity and total protein levels. However, determination of enzyme activity relative to total protein content (enzyme specific activity) revealed contrasting patterns. High dose intratracheal bleomycin instillation (500 micrograms) induced an increase in ACE activity relative to total protein. When a lower dose of bleomycin (50 micrograms) or when a 30-h exposure to 100% oxygen were used, both ACE and protein increased but enzyme specific activity did not change. In contrast, exposure to 100% oxygen for 48 h or to alpha-naphthylthiourea, an agent that rapidly induces protein edema without cell injury, caused a decrease in enzyme specific activity. The enzyme found in lavage fluid in these models is identical to the lung tissue enzyme with respect to cofactor requirements, inhibition by captopril, and has an apparent molecular weight of 175 kDa by SDS-polyacrylamide gel electrophoresis. These studies clearly refute the null hypothesis that lavage ACE levels in the injured lung merely reflect altered bulk protein transmigration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449832     DOI: 10.1164/ajrccm/137.3.531

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  5 in total

Review 1.  The adult respiratory distress syndrome.

Authors:  N F Voelkel
Journal:  Klin Wochenschr       Date:  1989-06-01

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

3.  Angiotensin-converting enzyme activity in serum and bronchoalveolar lavage fluid after damage to the alveolo-capillary barrier in the human lung.

Authors:  R F De Jongh; W A De Backer; R Mohan; P G Jorens; F J van Overveld
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

4.  Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man.

Authors:  R J MacFadyen; K R Lees; J D Gemmill; W S Hillis; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

5.  LPS-induced effects on angiotensin I-converting enzyme expression and shedding in human pulmonary microvascular endothelial cells.

Authors:  M I Hermanns; A M Müller; M Tsokos; C J Kirkpatrick
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-10-29       Impact factor: 2.416

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.